{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-021541","form_type":"8-K","ticker":"OCGN","cik":"0001372299","company_name":"Ocugen, Inc.","filed_at":"2026-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.935106+00:00","generated_at":"2026-05-15T08:34:47.482557+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"Ocugen furnishes investor presentation; no material new details available from filing","bullets":["Exhibit 99.1 presentation attached to 8-K but full content not provided in the filing excerpt.","Ocugen (OCGN) continues to highlight gene therapy pipeline; no financial or clinical updates disclosed.","Presentation posted on company website for investor use; no specific new events or numbers reported."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-021541","json":"https://secwatch.observer/filing/0001628280-26-021541.json","markdown":"https://secwatch.observer/filing/0001628280-26-021541.md","text":"https://secwatch.observer/filing/0001628280-26-021541.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372299/000162828026021541/0001628280-26-021541-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372299/000162828026021541/ocgn-20260326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:34:47.482557+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}